COMPASS 31 – A Refined and Abbreviated Composite Autonomic Symptom Score (P03.019)
COMPASS 31 – A Refined and Abbreviated Composite Autonomic Symptom Score (P03.019)
复制标题
DOI：
10.1212/wnl.80.7_supplement.p03.019
复制
发表时间：
2013-02
期刊：
影响因子：
9.9
通讯作者：
D. Sletten;J. Mandrekar;P. Low;W. Singer
中科院分区：
文献类型：
--
作者：
D. Sletten;J. Mandrekar;P. Low;W. Singer
目的：开发一种更新的，简洁的，统计学上可靠的工具，用于自主神经症状的标准化评估。背景：自主神经症状特征（ASP）是一种评价自主神经症状严重程度和分布的完善问卷。使用一个子集的问题，我们已经产生了一个有效的评分工具，复合自主症状评分（COMPASS）。容易出错的评分算法、耗时的管理和缺乏内部一致性，需要重新设计为更新的、更简洁的、统计学上可靠的和广泛适用的自主症状量化工具。设计/方法：以405名健康对照者的ASP为基础，采用Cronbach α系数评价COMPASS的内部一致性。应用一个简化的评分算法，然后使用探索性因子分析与正交旋转和特征值计算，以提取内部一致的域，并降低维数。随后进行了专家修订，以删除冗余内容并保留临床重要问题，并对新仪器进行了最终评估。结果：新的，简化的评分算法单独导致更高的克朗巴赫α值在所有领域。因子分析显示7个领域，共保留54个问题。经专家修订后，问题和领域进一步减少，剩下的问题共有31个，分属6个领域（COMPASS 31）。与COMPASS相比，内部一致性措施有了很大改进。在适当加权后，该仪器提供从0到100的自主症状评分。结论：COMPASS 31是一种精确的、内部一致的、显著简化的自主神经症状定量测量方法。它是在原有ASP和COMPASS的基础上，采用了一种简化的评分算法，适合于在自主学习研究和实践中广泛使用。支持单位：部分由美国国立卫生研究院（NS 32352自主神经疾病计划项目; NS 44233多系统萎缩的发病机制和诊断，U 54 NS 065736自主神经罕见疾病临床联盟和K23 NS 075141），马约CTSA（UL 1 RR 24150）和马约基金。披露：Sletten博士没有什么可披露的。曼德瑞卡博士没有什么可透露的。刘博士因与切尔西、辉瑞公司和WR医疗公司的活动而获得个人报酬。做顾问Low博士以《自主神经科学》编辑的身份获得了个人报酬。辛格博士收到了雅各布斯制药公司的付款。
OBJECTIVE: To develop an updated, concise, and statistically robust instrument for the standarized assessment of autonomic symptoms. BACKGROUND: The Autonomic Symptom Profile (ASP) is a well-established questionnaire evaluating severity and distribution of autonomic symptoms. Using a subset of questions, we have generated a validated scoring instrument, the composite autonomic symptom score (COMPASS). An error-prone scoring algorithm, time-consuming administration, and lack of internal consistency necessitated a redesign to an updated, more concise, statistically solid, and broadly applicable tool for autonomic symptom quantification. DESIGN/METHODS: We assessed the internal consistency of COMPASS using Cronbach alpha coefficients based on the ASP of 405 healthy control subjects. Applying a simplified scoring algorithm, we then used exploratory factor analysis with orthogonal rotation and Eigenvalue calculations to extract internally consistent domains and to reduce dimensionality. This was followed by expert revisions to eliminate redundant content and to retain clinically important questions, and final assessment of the new instrument. RESULTS: The new, simplified scoring algorithm alone resulted in higher Cronbach alpha values in all domains. Factor analysis revealed 7 domains with a total of 54 questions retained. Expert revisions resulted in further reduction of questions and domains with a remaining total of 31 questions in 6 domains (COMPASS 31). Measures of internal consistency were much improved compared to COMPASS. Following appropriate weighting, this instrument provides an autonomic symptom score from 0 to 100. CONCLUSIONS: COMPASS 31 is a refined, internally consistent, and markedly abbreviated quantitative measure of autonomic symptoms. It is based on the original ASP and COMPASS, applies a much simplified scoring algorithm, and is suitable for widespread use in autonomic research and practice. Supported by: In part by National Institutes of Health (NS 32352 Autonomic Disorders Program Project; NS 44233 Pathogenesis and Diagnosis of Multiple System Atrophy, U54 NS065736 Autonomic Rare Disease Clinical Consortium, and K23NS075141), Mayo CTSA (UL1 RR24150), and Mayo Funds. Disclosure: Dr. Sletten has nothing to disclose. Dr. Mandrekar has nothing to disclose. Dr. Low has received personal compensation for activities with Chelsea, Pfizer Inc, and WR Medical Inc. as a consultant. Dr. Low has received personal compensation in an editorial capacity for Autonomic Neuroscience. Dr. Singer has received payments from Jacobus Pharmaceuticals.